Navigation Links
AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
Date:11/12/2012

sis. All three trials were conducted in patients with non-cancer pain and documented OIC, who require daily opioid therapy.

Enrolment is complete for the open-label, randomized, 52-week long-term safety trial (KODIAC-08) and the trial is expected to be completed by Q1 2013.

Naloxegol is currently considered a Schedule II controlled substance by the US Drug Enforcement Administration (DEA) based on structural relatedness to noroxymorphone. AstraZeneca has conducted the studies necessary to evaluate the abuse potential and dependence-producing properties of naloxegol in support of obtaining decontrol. A petition for the decontrol of naloxegol was submitted to the DEA in March 2012 and subsequently accepted for review. Commercialisation and launch in the US will be subject to both FDA approval and DEA schedule determination.

Nektar to Host Conference Call with Investors and AnalystsNektar Therapeutics (Nasdaq: NKTR) will host an investor and analyst conference call today to discuss these results.  The call will begin at 8:15 a.m. Eastern Standard Time (EST)/5:15 a.m. Pacific Standard Time (PST).
A link to the live conference call webcast is accessible from the home page of the Nektar website: http://www.nektar.com.

To access the conference call live by telephone, please follow these instructions:

Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Passcode: 70465377 (Nektar Therapeutics is the host)

About Naloxegol
Naloxegol is a peripherally-acting mu-opioid receptor antagonist being investigated for the treatment of constipation (opioid-induced constipation or OIC) as a side effect of prescription opioid pain medicines.

Top-line results of the Phase II study of naloxegol (formerly NKTR-118) were previously presented at the American College of Gastroenterology Annual Clinical
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
2. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
3. AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma
4. Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences
5. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
6. Apexigen Announces Initiation of Clinical Trials By Its Partner, Simcere Pharmaceutical Group
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
8. Boston Childrens Hospital announces international genomics competition winner
9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
10. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
11. AMRI Announces Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:12/25/2014)... The report “Service Quality Management and ... Provider Type - Global Advancements, Worldwide Forecasts & Analysis ... analysis and forecasting of revenues. , Browse 152 ... and in-depth TOC on “Service Quality Management (SQM) and ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
(Date:12/24/2014)... December 23, 2014 GMO corn cases filed ... are in the process of being consolidated in a Kansas ... Re: Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 ... , Management of the Syngenta GMO corn multidistrict litigation (MDL) ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Doyle gathered over 100 executives and leaders of ... to preview his new economic growth package. These ... leadership, The Wisconsin Technology Council as well many ... capitalists. The message they heard from governor was ...
... Patients Compensation Fund could be illegal , ,While ... support yesterday for Gov. Jim Doyles Grow Wisconsin program, ... support, but takes issue with the provisions for the ... criticism for Doyles proposed use of funds from the ...
... Its Saturday night. Your 4 year old has stomach pains, and ... all sorts of personal medical information including her medical history and ... and you try to remember if you told the person at ... two as the triage nurse does not see bleeding or an ...
Cached Biology Technology:Governor Gathers Biotech Leaders at his Residence 2Republicans criticize Doyles growth package 2Republicans criticize Doyles growth package 3Republicans criticize Doyles growth package 4Childrens Medical Hospital of Wisconsin Goes Digital 2Childrens Medical Hospital of Wisconsin Goes Digital 3Childrens Medical Hospital of Wisconsin Goes Digital 4
(Date:1/22/2015)... , Europe,s ... European Patent Office to present a video retrospective of the most ... featured: Christofer Toumazou and Sophie Wilson   ... of the Award   Starting on 22 January 2015 ...
(Date:1/22/2015)... Infinisource has launched its new NXG series of time ... sets a higher standard for collecting attendance and labor data ... plug-and-play installation, touch screen interface and seamless connection to cloud-based ... collection solution for the small to mid-size employer. ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 This ... media watermarking and fingerprinting markets. Watermarking aims to ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3Infinisource's NXG series sets new time clock standard 2The Global Watermarking and Fingerprinting Markets 2
... 2009, six leading ecosystem researchers will share with lawmakers key ... This science briefing is part of the annual Association ... Cities around the nation are bracing for the impacts ... states to drought in the west, water will be at ...
... relief and a good cleansing for millions of Americans, ... pathogenic bacteria, according to a surprising new University of ... high-tech instruments and lab methods to analyze roughly 50 ... New York City, Chicago and Denver. They concluded ...
... of The 2009 Lasker Awards, announced today, represent the ... to a revolutionary cancer treatment and the tremendous promise ... portend a potential $700 million global market for new ... Genetic Engineering & Biotechnology News (GEN, www.genengnews.com ...
Cached Biology News:Daily bathroom showers may deliver face full of pathogens, says CU-Boulder study 2Daily bathroom showers may deliver face full of pathogens, says CU-Boulder study 3Daily bathroom showers may deliver face full of pathogens, says CU-Boulder study 42009 Lasker Awards recognize promise of stem cells -- global market could top $700 million 2
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
OmniSlide thermal Cycler for slide applications. 20 slide capacity. Humidity Chamber. Slide Rack can be transferred directly to Wash Module to avoid handling individual slides....
HyPro 100, includes 5 x HyPro20 and HyPro Cabinet. 100 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
HyPro 20 system for slide hybridization. 20 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
Biology Products: